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MHC-restricted CD8+ T cells are important during infection with the intracellular protozoan parasite Trypanosoma cruzi, the
causative agent of Chagas disease. Experimental studies performed in the past 25 years have elucidated a number of features
related to the immune response mediated by these T cells, which are important for establishing the parasite/host equilibrium
leading to chronic infection. CD8+ T cells are specific for highly immunodominant antigens expressed by members of the trans-
sialidase family. After infection, their activation is delayed, and the cells display a high proliferative activity associated with high
apoptotic rates. Although they participate in parasite control and elimination, they are unable to clear the infection due to their
low fitness, allowing the parasite to establish the chronic phase when these cells then play an active role in the induction of heart
immunopathology. Vaccination with a number of subunit recombinant vaccines aimed at eliciting specific CD8+ T cells can reverse
this path, thereby generating a productive immune response that will lead to the control of infection, reduction of symptoms,
and reduction of disease transmission. Due to these attributes, activation of CD8+ T lymphocytes may constitute a path for the
development of a veterinarian or human vaccine.
1. Relevance of Chagas Disease
Trypanosoma cruzi is the etiologic agent of Chagas disease,
also known as American trypanosomiasis. Infection with this
protozoan parasite currently affects approximately 10 million
people (WHO 2013) and is the major cause of nonischemic
heart disease worldwide. In Latin America, Chagas disease
causes an annual loss of 750,000 years of productivity in
addition to a loss of 1.2 billion dollars. Despite the fact that
most infected individuals are present in endemic areas of
Latin America, an increasing number of cases have been
reported outside these areas in recent decades, mainly due to
the migratory flux of infected people to other regions. Thus,
it is estimated that there are approximately 300,000 currently
infected people in the United States, 5,500 in Canada, 80,000
in Europe, 1,500 in Australia, and 3,000 in Japan.
Furthermore, there is no effective chemotherapeutic
treatment against this disease. Drugs conventionally used
for the treatment of infected individuals were developed in
the 1960s (nifurtimox and benznidazole). Being outdated,
these drugs are highly toxic, have variable efficacy and weak
activity in immunocompromised patients, and require long
treatments, and the cost of treatment is high, starting from
USD 1,000 per year per patient.
Currently, vectorial control using insecticides is the main
method to prevent the transmission. Although vectorial
transmission has been controlled in some Southern Cone
countries [1] there are reports of insect vector resistance to
insecticides in other regions, such as theGranChaco [2]. Still,
some insect vector species are particularly difficult to control
by insecticides; thus, it is likely that control by insecticides
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will only keep transmission at low levels without eradicating
the disease [2].
It should be also noted that vector control does not block
transmission by secondary routes, which are the main modes
of transmission outside of endemic areas or where the insect
vector has been controlled or is absent. The secondary routes
are (i) mother to child transmission and blood transfusion
and (ii) organ transplantation from infected people. In order
to reduce infections by blood or organ transplants, it is critical
to analyze donated blood and organs for the presence of
parasites [3].
Considering the number of affected people, the economic
impact in endemic areas, the recent dispersion of infected
people, the inefficiency and cost of treatment, and the lack of
effective methods to control transmission, the difficult task of
developing a vaccine against infection by Trypanosoma cruzi
has been resurrected.
2. Relevance of the Development of
a Vaccine for Chagas Disease
In a recent study, Lee et al. generated a computer model
to simulate the economic impact of a prophylactic vaccine
for Chagas disease in Latin America [4]. This study demon-
strated that a vaccine would be beneficial even if it had low
protective efficacy (25%), even in places where the risk of
becoming infected is less than 1%, and even if the vaccine cost
isUSD20.00.A vaccine costingmore thanUSD200.00would
only be economically advantageous if it had efficacy greater
than 50% and was used in places where the risk of becoming
infected was greater than 20%. Based on these studies, several
groups have been focusing on the development of a vaccine
against Chagas disease.
3. Clinical Data of Chagas Disease
Chagas disease has two distinct clinical phases: acute and
chronic. In the acute phase, individuals exhibit patent
parasitemia that begins one to two weeks after infection.
In this phase, the infection has variable symptoms from
asymptomatic to intensely symptomatic and includes risk of
death. Except Roman˜a sign that is characterized as a swelling
at the site of infection, signs and symptoms related to the
acute phase of Chagas disease symptoms are most of the
times nonspecific and consequently it is difficult to detect the
infection in the initial stage. In the acute phase, there is strong
activation of the immune system with high levels of plasma
cytokines, intense activation of B and T lymphocytes, and
inflammatory reactions in the infected tissues (WHO 2013).
In most cases, the acute phase parasitemia is controlled
gradually, presumably due to the host adaptive immune
responses, and it is reduced to subpatent levels. After control-
ling acute parasitemia, the chronic phase is initiated. In this
phase, it is possible to detect specific antibodies by different
serological tests and, in many patients, the parasites can be
isolated by blood culture or by xenodiagnosis. These tests are
routinely used for parasitological exams (WHO 2013). The
chronic phase can last for the entire life of the patient and is
initially asymptomatic. After years of initial contact with the
parasite, 40% of infected persons develop symptomatology,
while the remaining 60% remain asymptomatic throughout
life.
In approximately 30% of cases, patients develop cardiac
symptoms (associated with severe myocarditis), and in the
remaining 10%, there is damage to the digestive system
with infiltration of lymphocytes and neuronal degeneration,
leading to the development of megacolon or megaesophagus
[5]. Despite the fact that the causes of the immunopathology
are not precisely known, several evidences indicate that
parasite persistence is a critical factor for the development
of Chagas disease [5, 6]. Accordingly, extensive destruction
and fibrosis of the heart would be a result of the inflammatory
reaction required to eliminate the parasites in the tissues [7].
Nevertheless, whether the parasite has to be present within
the heart tissue is still a debatable question. Although most
studies have found parasites in this tissue by using detection
of DNA by PCR, live parasite has not been detected [8].
4. Immune Response During T. cruzi Infection
4.1. Patients with Chagas Disease. In order to establish a
successful chronic infection, theremust be a balance between
parasite multiplication in the tissues and host immune
control that will keep the host alive. In this regard, the host
immune response is part of the parasite life cycle. Without
proper control of the immune response, the hostmay die, and
the parasite life cycle is broken.
During human infection, protective antibodies are
mainly directed towards the Gal epitope containing the 𝛼Gal
𝛼1,3-Gal 𝛽1,4-GlcNAc, which is present in the majority of
mucin glycoproteins on the surface of T. cruzi trypomastig-
otes [9]. These antibodies are present in high concentrations
during the patent infection and the entire chronic phase
and are markers for active human infection [10]. These
antibodies kill the parasite independently of the presence of
complement or cells, and their activity is facilitated by the
presence of specific antibodies for the catalytic domain of
the TS enzyme that inhibit sialic acid addition to the surface
of trypomastigotes [11]. Whether antibodies directed to
other parasite targets are also important in immunity against
infection remains to be determined.
Specific T lymphocytes against T. cruzi antigens can be
detected in most individuals during chronic infection [12].
There is no direct evidence that these cells are important for
host resistance. However, it is possible that they exert antipar-
asitic activities similar to those observed during experimental
infection (see below). Events leading to the depression of the
immune response, such as acquired immunodeficiency or
immunosuppressive treatments (e.g., AIDS), cause relatively
rapid onset of symptomatic forms of the disease in some
patients with Chagas disease [13]. In some cases, there is
reappearance of patent parasitemia, that is, characteristic of
the acute stage of infection [14]. Therefore, it seems clear that
the adaptive immune response maintains the low levels of
parasitemia observed in patients with Chagas disease during
the chronic phase.
Comparative studies of the cellular immune responses
in patients who develop clinical symptoms, such as chronic
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chagasic cardiomyopathy (CCC), have led to conflicting
results. Some researchers have associated the high production
of IFN-𝛾 with CCC [15, 16]. Based on this, polymorphisms
in the promoter gene regions that encode BAT-1 and IL-10
anti-inflammatory proteins suggest that production of IFN-𝛾
is more frequent in patients with CCC [17, 18]. Additionally,
Tregs have been correlated with clinical CCC improvement
[19].Thus, patients able to control the inflammatory response
in the myocardium may have less tissue damage and milder
disease. In contrast, other groups have suggested the opposite:
higher production of proinflammatory cytokines, such as
IFN-𝛾 and IL-17, correlates with an improvement in the clin-
ical picture of chronic Chagas disease [20, 21]. In these cases,
CCCwould develop due to increased expression ofmolecules
that inhibit the activation of specific T lymphocytes, leading
to exhaustion of the specific immune response [21, 22].
4.2. Experimental Murine Models. In an attempt to identify
the molecules and mechanisms associated with resistance to
T. cruzi infection, immunologists have employed a number
of genetically modified mice. It has been described that resis-
tance toT. cruzi infection requires activation of the innate and
adaptive immune responses directed at different stages of par-
asite development. In the case of the innate immune response,
several mechanisms operate in order to partially control
multiplication of the parasite. Accordingly, mice that are
genetically deficient in Toll-like receptors (TLRs) and their
adaptors (MyD88 and TRIF), the NOD-like receptors (NLR),
or inflammasome activators are more susceptible to experi-
mental T. cruzi infection [5, 23, 24]. These molecules provide
signals for the secretion of mediators, such as TNF-𝛼, IFN-
𝛾, and IL-12, which in turn are critical for resistance against
experimental infection [25]. Upon activation of the innate
immune response, there is intense activation of CD4+ and
CD8+ T lymphocytes, as well as B cells. Likewise, in innate
immunity, mice genetically deficient in CD4 or CD8 are also
extremely susceptible to infection [26]. These T lymphocytes
act by producing type 1 cytokines, such as IFN-𝛾. However, in
the case of CD8+ T lymphocytes, direct cytotoxicitymediated
by perforin may be important for resistance against infection
with some strains of T. cruzi [27–29]. Finally, in addition to
classical innate and adaptive immune responses, NK cells are
also activated and produce IFN-𝛾 [30].
5. Role of CD8+ T Cells during
T. cruzi Infection
5.1. Patient with Chagas Disease. In the cardiac lesions of
chronically infected individuals, the inflammatory infiltrate
is largely dominated by CD8+ T cells with a minor propor-
tion of CD4+ T cells, B cells, plasma cells, macrophages,
eosinophils, and mast cells [22]. This predominance suggests
an important role for CD8+ T cells during infection [31–33].
Given the difficulty of obtaining cardiac tissue from chagasic
individuals, analysis of the specificity of intracardiac CD8+
T lymphocytes from patients with Chagas cardiomyopathy is
limited to a single study involving a small group of patients
withHLA-A0201 [34]. In this study, it was shown that patients
had specific CD8+ T lymphocytes to some of the 26 peptides
tested from FL-160 or cruzipain antigens in the peripheral
blood. In the same study, cells specific for one of the cruzipain
peptides were isolated from the cardiac tissue of a patient.
Cells with this same specificity were also present in the
peripheral circulation [34].
The frequency of specific CD8+ T lymphocytes was
lower in the peripheral blood of chagasic patients with
severe disease than in asymptomatic or mildly symptomatic
patients. Furthermore, the stage of differentiation of these T
cells was different between these two groups. Patients with
severe disease had fewer early memory cells (CD45RA−,
CD27+, and CD28+) and a higher number of late memory
cells (CD45RA−, CD27−, and CD28−). These results suggest
that protection against this disease may be associated with
an increased frequency of highly competent CD8+ T lym-
phocytes in the early state of differentiation [35]. Infected
people in the chronic phase without cardiac symptoms or
withmild symptoms had a higher frequency of specific CD8+
T lymphocytes producing IFN-𝛾 than people who developed
severe symptoms. Therefore, the severity of the disease may
be related to the specificity and quality of the CD8+ T
cell response generated during infection [20]. In addition,
because it is a chronic infection and the antigen persists, it
is possible that the cellular response is driven to exhaustion
[35]. However, this is not the case of the mouse model. One
possible explanation is that themurinemodel has a very short
life span when compared to humans, and then, mice do not
develop exhausted T cells.
The specificity of the CD8+ T lymphocyte response was
analyzed, and several TS epitopes restricted to HLA-A0201
were identified. Due to the high degree of polymorphism of
the human HLA plus the divergent specific response among
different strains of T. cruzi, it is difficult to establish a correla-
tion between the human immune response and resistance to
infection [36]. To identify the target specificity of the CD8+
T lymphocyte response from patients in the chronic phase,
Alvarez et al. (2008) carried out extensive screening of TS-
derived peptides predicted to bind common HLAmolecules.
The most prevalent HLAs in the population were divided
into six supertypes comprising one or more HLA alleles
present in 95%of the human population irrespective of ethnic
origin. The results of this study indicated that promiscuous
TS epitopes, which were able to bind to HLA-A02, HLA-
A03, and HLA-A24, are the main targets of memory CD8+ T
lymphocytes in chronic chagasic patients. Responses to these
epitopes were detected in 13 of 25 asymptomatic individuals.
This approach suggests that a specific set of HLAs restricted
to these peptides can be used to measure the functional
activity and frequency of CD8+ T lymphocytes specific for
T. cruzi in a wide variety of patients with Chagas disease
without having to perform HLA typing. Furthermore, it was
noted by the authors that the frequency of specific CD8+
T lymphocytes producing IL-2 was significantly reduced
in chronically infected patients [36]. Considering that the
parasite load is extremely low in these individuals, the authors
proposed that long-term parasite persistence can result in a
specific T lymphocyte population with low capacity for self-
renewal.While this work was only focused on the response to
TS proteins, thus only examining a fraction of all the possible
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CD8+ T lymphocytes specific for T. cruzi, it is significant that
more than 50% of the evaluated subjects responded to at least
one TS epitope.
5.2. ExperimentalMurineModels. A fewhours after penetrat-
ing the host cell, T. cruzi escapes from the parasitophorous
vacuole and enters the cytosol, where it differentiates into
amastigotes and begins its replication. Once the parasite is in
the cytosol, its secreted antigens become available to be pro-
cessed and presented viaMHC-I [69].The relevance of CD8+
T lymphocytes in immunity against experimental infection
with T. cruzi has been demonstrated by different methods.
Studies have used 𝛽2-microglobulin-deficient mice, which
lack cells restricted toMHC-Imolecules (such asNKcells and
CD8+ T lymphocytes),mice deficient in theCD8molecule, or
mice depleted of CD8+ T cells using monoclonal antibodies.
In all cases, the absence of CD8+ T cells leads to extreme sus-
ceptibility to experimental infection [5]. SpecificCD8+ T cells
promote resistance to infection byT. cruzi through IFN-𝛾, but
direct perforin-mediated cytotoxic activity can also play an
important role depending on the strain of T. cruzi [5, 27, 28].
The mechanisms involved in the processing and presen-
tation of these antigens to CD8+ T cells are unknown. There
is evidence that CD11c+ dendritic cells are important for the
initiation of the immune response that occurs in the draining
lymph nodes [65, 70]. Afterwards, the CD8+ T lymphocytes
recirculate and enter the spleen. This requires the expression
of the chemotactic receptor S1PR1 (sphingosine 1 phosphate
receptor) on the surface of lymphocytes, as egress can be
blocked by use of the drug FTY720 [65].
The response of CD8+ T lymphocytes during experi-
mental infection with T. cruzi has kinetics distinct from
those observed with viruses or bacteria that cause self-
limiting infections, such as influenza, LCMV, or Listeria.
In these cases, the peak of the immune response measured
by the frequency of specific CD8+ T lymphocytes is 7 to
15 days [71]. After T. cruzi infection, we and others have
observed that the peak of the immune response occurs after
approximately 30 days [27, 39, 72, 73]. These delayed kinetics
of the immune response most likely allow the parasite to
establish tissue infection before they can be eliminated by
CD8+ T lymphocytes. The precise mechanisms that control
this altered kinetics are not known, but we have observed
that the parasite load is an important factor controlling the
timing of the immune response.Thus, increasing the parasite
inoculum leads to acceleration of the parasitemia/infection
onset, which in turn triggers acceleration of specific CD8+ T
lymphocyte generation [73].
In contrast to what is seen in common viral or bacterial
infections, we do not observe a marked decrease (contrac-
tion) in the immune response. As shown in Figure 1, the
frequencies of specific CD8+ T cells remain high for long
periods of time. Furthermore, the phenotype of these CD8+ T
lymphocytes is maintained as T effector memory (TEM) cells
through this period, and this is linked to parasite persistence.
Effective treatment with an antitrypanocidal drug led to the
contraction of the number of CD8+ T cells and a change in
their phenotype to CD62LLow [74].
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Figure 1: Kinetics of the immune response mediated by CD8+
lymphocytes after experimental infection with viruses or with T.
cruzi.
Importantly, the immune response mediated by CD8+ T
cells generated after experimental infection does not always
allow host survival. Mice from susceptible strains, such
A/Sn, uniformly die after infection with few parasites [75].
However, after infection of resistant mice, such as C57BL/6,
the immune response mediated by CD8+ T lymphocytes
protects the animals from death. Nevertheless, these animals
are unable to completely eliminate the parasites, which drives
them to the chronic phase of infection. Thus, under no
circumstances can the immune response mediated by CD8+
T lymphocytes eliminate T. cruzi. In contrast, genetic vac-
cination with a DNA plasmid and recombinant adenovirus
expressing an immunodominant T. cruzi antigen amastigote
surface protein 2 (ASP-2) is able to induce a potent immune
response mediated by CD8+ T lymphocytes that protects
highly susceptible A/Sn mice [28, 76]. These animals not
only survive the acute infection but also do not develop
chronic Chagas disease and have no detectable circulating
parasites. This observation has created a paradox, since both
experimental infections and genetic immunizations induce
CD8+ T cells that are capable of secreting the antiparasitic
mediator IFN-𝛾 and mediating potent cytotoxic lymphocyte
activity in vivo. To explain this paradox, we hypothesize that
the specific CD8+ T lymphocytes induced by the adenovi-
ral vector expressing the ASP-2 antigen (AdASP-2) or by
experimental infection present distinct properties that either
confer immunoprotective ability in the former or prevent
an effective response in the latter. In order to identify this
factor, we made a detailed comparison of the two immune
responses. We observed that there was a high degree of
similarity in the immune responses induced by AdASP-2
and by infection with T. cruzi. After 19 days, the immune
responses had similar magnitudes and were mediated by
multifunctional lymphocytes capable of translocating the
CD107a molecule to the cell surface as well as accumulating
IFN-𝛾 and TNF-𝛼 after in vitro stimulation with cognate
peptide [75]. Moreover, these specific lymphocytes were
highly cytotoxic in vivo. Among the few differences, there was
amarkedly accelerated expansion of the CD8+ T cell immune
response induced by AdASP-2 compared to T. cruzi infection
[75]. When we evaluated the proliferation of specific CD8+ T
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lymphocytes, we found that a higher frequency of cells prolif-
erated following infection when compared to immunization
with AdASP-2 [75]. However, as mentioned above, their
frequencies were similar. This discrepancy was explained
by a significant increase in the frequency of specific CD8+
T lymphocytes with a proapoptotic phenotype in infected
animals compared to immunized animals. Therefore, the
main difference observed when comparing the two immune
responses was the viability (fitness) of specific CD8+ T
lymphocytes.Whereas immunization with AdASP-2 induced
highly viable specific CD8+ T cells, infection led to intense
expansion and apoptosis. In order to determine the molec-
ular basis for this phenomenon, we analyzed a total of 28
surface molecules, including adhesion molecules, functional
markers, and receptors involved in T lymphocyte survival
(Figure 2). The main difference observed was that specific
CD8+ T cells induced by experimental infection showed a
higher expression of apoptotic CD95 (Fas) receptor com-
pared with specific CD8+ lymphocytes frommice vaccinated
with AdASP-2 [75]. Not only these cells expressed high levels
of CD95 on the surface, but signaling through this molecule
in vitro with anti-CD95 mAb led to their death. In contrast,
specific CD8+ T lymphocytes induced by vaccination with
AdASP-2were refractory to death induced by anti-CD95 [75].
These striking differences in the quality of the immune
response induced by immunization with the AdASP-2 and
by T. cruzi infection provide an important basis to explain
the suboptimal immune response mediated by CD8+ T
cells during infection. In addition, this difference may also
explain the success of genetic vaccination with recombinant
adenoviral vectors. Indeed, concomitant injection of AdASP-
2 and T. cruzi led to (i) a strong specific immune response
mediated by CD8+ T lymphocytes; (ii) lower expression
of CD95, which led to resistance to anti-CD95-mediated
apoptosis; (iii) protective immunity against experimental
infection with T. cruzi [77] (Figure 3).
Another important factor that characterizes the immune
response mediated by CD8+ T lymphocytes during experi-
mental T. cruzi infection in mice is the fact that it is restricted
to few epitopes. This occurs despite the great number of pos-
sible CD8 epitopes present in the parasite. This phenomenon
is called immunodominance. All the immunodominant epi-
topes described thus far are expressed by members of the TS
family of T. cruzi.
Several molecular mechanisms leading to the immun-
odominance of CD8+ T cells during infection are known,
some of which are related to the formation of the peptide-
MHC-I complex on the surface of APC. The following are
important for the formation of these complexes: (i) abun-
dance of the antigen; (ii) availability of APC; (iii) enzymatic
processing by proteasomes and other proteolytic enzymes;
(iv) translocation of peptides into the endoplasmic reticulum
by transporter proteins; (v) binding of peptides to MHC-I.
The second group of factors that influence immunodomi-
nance are related to the activation of CD8+ T lymphocytes:
(i) frequency of cell precursors in the repertoire capable of
recognizing the peptide-MHC-I complex; (ii) affinity of the
T cell receptors; (iii) CD8+ T lymphocyte competition by the
APC during priming. Other factors, such as regulation of
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Figure 2: Surface molecules expressed by specific CD8+ T lympho-
cytes following infection with T. cruzi and vaccination with AdASP-
2.
specific immune responses, the ability of pathogens tomutate
their recognized epitopes, expression of specific antigens
on the different evolutionary stages, modulation of antigen
expression at different stages of infection, and direct inhibi-
tion of mechanisms involved in the formation of the peptide-
MHC-I complex could also theoretically influence immun-
odominance, but examples have not yet been described.
Due to the genetic restriction byMHC-I molecules in the
case of CD8+ T cells, 90% of immunodominance is linked
to the fact that only 1% of peptides can bind MHC-I with
affinity sufficient to induce a response mediated by CD8+
T lymphocytes. This is related to the structure of MHC-I
rather than the selective pressure by an organism to prevent
the host CD8+ T lymphocyte response [78]. Because of the
genomic complexity of many infectious agents, most studies
seeking to define the molecular basis of immunodominance
of CD8+ T cell-mediated immunity have used viral models.
In a review article on immunodominance [79], they illustrate
the evolution of immune restriction mediated by CD8+
lymphocytes during vaccinia virus infection. The vaccinia
genome has the capacity to generate approximately 175,000
peptides of 8, 9, or 10mer (without considering the possibility
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Figure 3: Proposed model for activation of specific CD8+ lympho-
cytes during infection of T. cruzi in naive or AdASP-2 immunized
mice. Specific CD8+ T cells activated with APC containing T. cruzi
antigen induce higher levels of expression of CD95 and low viability
of T cells.This poor viability leads to a suboptimal response and host
pathology (death or chronic infection). In contrast, the contact of
APC pulsed with recombinant ADASP-2 activates specific CD8+ T
cells with low expression of CD95. In the second contact with APC
pulsed with T. cruzi antigen, specific CD8+ T cells with CD95low
phenotype develop a strong immune response driving parasite
elimination and promoting cure of the infection.
of alternative sequences of reads and posttranslational mod-
ifications). However, only 20% of these peptides are released
after processing by the proteasome and other proteases
(35,000 peptides). Although transport to the ER via TAP
influences the selection of peptides that are made available to
bindMHC-I, such transport has little effect on the restriction
of epitopes during vaccinia infection, and approximately
30,000 peptides are transported. Even so, approximately 1% of
these peptides bindMHC-I (150 peptides). Once the peptide-
MHC-I complex is exposed on the surface of the APC, the
repertoire of CD8+ T lymphocytes can recognize at least 50%
of these epitopes (75 peptides). However, only 50 peptides
are recognized, and these make up 90% of the response to
vaccinia virus. Finally these 50 vaccinia peptides that are
recognized during experimental infection, eight represent
more than 50% of the CD8+ T lymphocyte response observed
against infection.
As mentioned above, the antigen targets of the immune
response mediated by CD8+ T cells during T. cruzi exper-
imental infection are of TS family proteins [27, 72, 73, 80,
81] (Table 1). The molecular basis and biological significance
of immunodominance are unknown. It is possible that the
restriction of the number of known parasite epitopes may
be important for establishing the necessary balance between
the parasite and the host in order to keep the host alive
without eliminating the pathogen, thus leading to chronic
infection [5, 82]. Immunodominant epitopes vary by T. cruzi
strain, such that an epitope can be immunodominant during
infection with one strain and subdominant with another in
genetically identical hosts [39, 72].
Despite evidence of strong immunodominance during
T. cruzi experimental infection, to date only one study
has attempted to determine the cellular/molecular basis
for this phenomenon. In this study, it was reported that
infected homozygous C57BL/6 mice or heterozygous F1
mice (C57BL/6 X BALB/c) had similar CD8+ T lympho-
cytes responses to the MHC-I H-2Kb-restricted epitope
VNHRFTLV. In contrast, the immune response to the MHC-
I H-2Kd-restricted epitope IYNVGQVSI was significantly
reduced in heterozygous animalswhen compared to homozy-
gous BALB/c mice [72]. Such a discrepancy could not be
attributed to the CD8+ T lymphocyte repertoire or to low
MHC-I H-2Kd expression on the APC surface of heterozy-
gous mice. This phenomenon, which restricted the immune
response and generated strong immunodominance, could
be reproduced in other heterozygote strains of mice after
infection with T. cruzi. However, there was no difference in
the immune responses of homozygote and heterozygote ani-
mals following immunizationwith theAdASP-2 expressingT.
cruzi antigen [72]. Finally, in the same study, C57BL/6 mice
infected with two different strains of T. cruzi, both the Y
and CL-Brener strains, responded to the two immunodom-
inant epitopes simultaneously. Based on these results, it was
proposed that the strong immunodominance induced during
infectionwithT. cruzi occurred by the competition ofCD8+ T
lymphocytes generated during priming for a limited number
of infected APCs. This competition for APC is also called
competitive priming or immunodomination and has been
reported in some cases of experimental infection [72, 83].
These observations were independently confirmed in
studies showing that CD8+ T cells of H-2a infected mice
recognized a single immunodominant epitope in the ASP-
2 antigen. In contrast, CD8+ T cells from mice immunized
with recombinant genetic vaccines expressing the same T.
cruzi antigen recognized two other subdominant epitopes in
addition to the immunodominant epitope [84].
Despite the immunoprotective role of CD8+ T lym-
phocytes during the acute phase of experimental T. cruzi
infection, recent studies have proposed that a subpopulation
of these lymphocytes is eventually responsible for further
damage to heart tissue in the chronic phase. These lympho-
cytes produce perforin, but not IFN-𝛾, and have a greater
propensity to migrate to the heart tissue, causing tissue
damage leading to CCC [85].
5.3. CD8+ TCellMediated Immunity for VaccineDevelopment.
Based on the proven antiparasitic activity of CD8+ T cells,
several groups have tried to elicit specific CD8+ T cells
for vaccine development against Chagas disease. For that
purpose, subunit vaccines based on plasmid DNA, viral,
and bacterial vectors were used. The antigens pursued for
recombinant vaccines includeT. cruzi trans-sialidase, cruzain
(a cysteine proteinase), and the amastigote surface proteins
2, 3, 4, TcG1, TcG2, TcG4, TSA-1, and Tc24 (review references
[23, 80, 86–90]). In addition to subunit vaccines, other groups
are using attenuated parasites [90]. A more detailed list of
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Table 1: Immunodominant epitopes recognized by murine CD8+ lymphocytes after infection with T. cruzi.
Antigen Epitope MHC T. cruzi strain Reference
TS IYNVGQVSI H-2Kd Y [37]
ASP-2 VNHRFTLV H-2Kb Y [27]
ASP-2 TEWETGQI H-2Kk Y [38]
TSA ANYDFTLV H-2Kb Brazil [39]
TSA ANYKFTLV H-2Kb Brazil [39]
APC
TC
T. cruzi
elimination/
host cure
APC
Differentiation 
and recirculation
TEM
Vaccination                                            Infection 
with T. cruzi 
TEM
Proliferation
CD8+
CD8+ CD8+
CD95−TE CD95−TEM
CD27+/−CD27+/−
KLRG1+/− KLRG1+
Figure 4: Proposed model for activation of specific CD8+ lymphocytes expanded by genetic vaccination after infection with T. cruzi.
the vaccination studies performed with subunit vaccines is
shown in Table 2. Overall, the results of mouse vaccinations
provide strong evidence that the induction of specific CD8+ T
cells can elicit protective immunity against acute phase symp-
toms estimated by parasitemia and survival. In some cases,
vaccination also reduced or eliminated chronic symptoms in
these mouse models.
An important question is whether vaccination can
achieve complete parasite elimination from the host. In most
protocols of experimental vaccination, residual parasites
are still present and are mostly within tissues rather than
circulating in the blood. Therefore, vaccination may at least
lead to a decrease or cessation in transmission. Vaccinated
mice rarely show symptoms of acute or chronic disease.
Therefore, even if they carry tissue parasites they will be
asymptomatic. This picture resembles the ∼60% of chagasic
patients who also maintain residual parasites for their entire
lives yet still remain asymptomatic (indeterminate form of
the disease). Thus, it would be ethical to propose that a
satisfactory vaccination goal could be to lower the frequencies
of symptomatic individuals even if that means increasing the
frequency of asymptomatic individuals.
During our recent studies of genetic immunization, we
used the heterologous prime-boost vaccination regimen con-
sisting of priming with plasmid DNA followed by a booster
injection with replication defective human adenovirus type 5,
both carrying the ASP-2 gene of T. cruzi. In these studies, we
observed that our immunization protocol induced TE cells
(CD11aHigh, CD44High, CD127Low, and CD62LLow). These
cells formed a stable pool of functional long-livedCD8+ TEM
cells (CD11aHigh, CD44High, CD127High, and CD62LLow).
Their long-term survival required a functional IL-12/IL-23
signaling pathway. Most relevant for vaccine development
was the fact that these cells were resistant to immunological
erosion and mediated strong protective immunity against
experimental systemic infection with T. cruzi [76].
According to the current immunological paradigm of
vaccines, protective immunity is mainly mediated by T
central memory (TCM) cells, which proliferate intensely
during recall responses. After an infectious challenge, specific
TCM cells differentiate to TE cells, proliferate, and eliminate
the pathogen.This concept established that, after vaccination,
TCM cells act similarly to self-curing viral infections, such as
acute LCMV [91].
Based on this paradigm, we evaluated the importance of
CD8+ T cell differentiation, proliferation, and recirculation to
mediate their antiparasitic effects. In our case, we only had a
TEM pool to stimulate. We observed that specific TEM cells
differentiated into cells with a KLRG1High CD27Low CD43Low
CD183Low T-betHigh EomesLow phenotype and were capable of
simultaneously producing the antiparasitic mediators IFN-𝛾
andTNF-𝛼. Subsequently, we observed that the specificCD8+
T cells did not participate in a strong anamnestic immune
response, and the protective immunity they mediated was
insensitive to treatment with the cytostatic toxic agent
hydroxyurea, which drastically reduced their proliferation
[92].
We also evaluated the importance of T cell recirculation
by administering the immunosuppressive drug FTY720 to
vaccinated mice after challenge with T. cruzi. This drug
reduces lymphocyte recirculation by interfering with T cell
signaling via sphingosine-1-phosphate receptor-1 (S1Pr1).
This interference results in sustained inhibition of S1Pr1
signaling, effectively trapping T cells within the secondary
lymphoid without inhibiting T cell activation. FTY720
administration significantly impaired protective immunity,
supporting the hypothesis that T cell recirculation is critical
for protective immunity [65].
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Table 2: Summary of the different antigen delivery systems used for the induction of CD8+ T cells against experimental T. cruzi infection.
Delivery system Adjuvant T. cruzi antigen/gene Reference
Rec. protein Freund’s adjuvant TS [40]
Rec. Protein CpG ODN TS [41]
Rec. Protein CpG ODN Cruzipain [42]
Rec. protein Alum/CpG ODN ASP-2 [38]
[43]
Plasmid DNA None TSA-1 [44]
[45]
[46]
Plasmid DNA IL-12 TSA [47]
[48]
Plasmid DNA None TS [49]
[50]
[41]
Plasmid DNA None ASP-1 [51]
Plasmid DNA None ASP-2 [51]
[52]
[53]
[54]
[55]
Plasmid DNA None ASP-3 [56]
Plasmid DNA None ASP-4 [56]
Plasmid DNA None CRP [57]
Plasmid DNA None KMP11 [58]
Plasmid DNA None Tc24 [45]
Plasmid DNA IL-12/GM-CSF TcG1 [59]
Plasmid DNA IL-12/GM-CSF TcG2 [59]
Plasmid DNA IL-12/GM-CSF TcG4 [59]
Rec. adenovirus None TS [60]
ASP-2 [60]
Rec. Salmonella None Cruzipain [61]
Sendai virus None ASP-2 [62]
Yellow fever 17D None ASP-2 [63]
Rec. adenovirus + Rec. MVA None TSA [64]
Plasmid DNA + Rec. Adenovirus None ASP-2 [28]
Plasmid DNA + Rec. Adenovirus None ASP-2 [65]
Rec. influenza + Rec. Adenovirus None ASP-2 [65, 66]
Plasmid + Rec. MVA IL-12/GM-CSF TcG2/TcG4 [67]
Plasmid + Rec. protein IL-12/GM-CSF TcG1/TcG2/TcG4 [68]
Based on these observations, we propose a model
whereby large amounts of antigen-experienced CD8+ TEM
cells present following heterologous prime-boost vaccination
that differentiate and recirculate, rather than proliferate, are
critical for protective immunity Figure 4. Recent studies
using themurine LCMV infectionmodel reported that CD8+
T cells that provide long-term protective immunity are a
subpopulation of TEM cells with the same phenotype as
our T cells (CD44High CD62Low KLRG1High CD27Low CD43
(1B1)Low CD183Low T-betHigh EomesLow) and not classical
TCM.These cells have limited proliferative ability, recirculate,
and are also critical in the resistance to infection with
Listeria monocytogenes and vaccinia [93]. Together, these
observations point to a novel CD8+ T cell population that
provides long-term memory and can be used for T cell
vaccine development. Additionally, these two observations
challenge the paradigm that memory T lymphocytes need
to proliferate in order to mediate protective immunity and
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suggest that recirculation is indeed fundamental. This idea
had not been properly explored and may have important
implications in the development of new vaccines.
A current limitation of the experimental model ofT. cruzi
infection is the absence of information about the precise
location where CD8+ T lymphocytes eliminate infected cells.
BecauseT. cruzi can infectmany cell types and cause systemic
(or not) infection, it will be important to determine where
CD8+ T lymphocytes encounter infected cells. The fact that
our vaccinated animals were resistant to challenge with T.
cruzi infection by different routes (i.p. and s.c.) suggests that
it may also be useful for natural infections.
6. Concluding Remarks
Studies on the role of CD8+ T cells during T. cruzi infection
have elucidated extremely important information regarding
the interface of host/T. cruzi interactions and the equilibrium
they achieve to establish chronic infection. In addition, they
have openednewavenues for the development of a still elusive
veterinarian or human vaccine against Chagas disease.
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